ADN-1184

an antipsychotic agent with both 5-HT6 and 5-HT7 receptor antagonist activities; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Bieńkowski, Przemysław: 1 article (06/2016)
2.	Jastrzębska-Więsek, Magdalena: 1 article (06/2016)
3.	Kołaczkowski, Marcin: 1 article (06/2016)
4.	Mierzejewski, Paweł: 1 article (06/2016)
5.	Partyka, Anna: 1 article (06/2016)
6.	Wasik, Anna: 1 article (06/2016)
7.	Wesołowska, Anna: 1 article (06/2016)
8.	Bieńkowski, P: 1 article (02/2014)
9.	Kołaczkowski, M: 1 article (02/2014)
10.	Mierzejewski, P: 1 article (02/2014)

1.	Cognitive Dysfunction 06/01/2016 - "A novel arylsulfonamide derivative ADN-1184 has been developed that possesses a preclinical profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances. "
2.	Psychotic Disorders (Schizoaffective Disorder) 06/01/2016 - "A novel arylsulfonamide derivative ADN-1184 has been developed that possesses a preclinical profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances. "
3.	Catalepsy 02/01/2014 - "Notably, up to 30 mg·kg(-1) ADN-1184 did not impair memory performance in the passive avoidance test or elicit significant catalepsy and only modestly inhibited spontaneous locomotor activity (MED = 30 mg·kg(-1) i.p.). "